Product Details

Teva-Tolterodine LA

Tolterodine L-Tartrate
4 mg
SR Capsule


DIN/PIN/NPN

02412209

Manufacturer

Teva Canada Limited

Formulary Listing Date

2016-02-25  

Unit Price

0.9822

Amount MOH Pays

0.9822

Coverage Status

Limited Use Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

G04BD07

Interchangeable Products

DIN/ PIN/ NPN Brand name Unit Price Amount MOH pays
02412209 Teva-Tolterodine LA 0.9822 0.9822
02413159 Sandoz Tolterodine LA 0.9822 0.9822
02244613 Detrol LA 2.2306 0.9822
 

LU Clinical Criteria

LU Code Auth. Period Clinical Criteria
290 Indefinite

For patients with urinary frequency, urgency or urge incontinence who have:

Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.

Note: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.

Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g., dementia) and those who are already using other drugs with significant anticholinergic effects (e.g., tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.

 

EAP Criteria

NO

Product Monograph

View Monograph